Assistant Professor of Medicine at Indiana University School of Medicine, interested in the mechanisms of liver fibrosis and chronic liver disease

Dr. Ding is a William Warner Abercrombie professor of the Department of Pharmacology, Toxicology, and Therapeutics at KUMC. The Ding laboratory has been working on the role of autophagy in alcohol and drug-induced liver injury since 2009. The Ding Lab is particularly interested in how autophagy selectively removes cellular damage and excess organelles, such as mitochondria and lipid droplets, in hepatocytes. Dr. Ding has extensive expertise in organelle stress and quality control in cell death and innate immunity in the pathogenesis of alcohol-associated liver disease and liver cancer.

Dr. Sudha Kodali obtained her medical degree from India and completed her residency training in Internal Medicine in Texas followed by fellowship in Gastroenterology and Hepatology at University of Alabama in Birmingham, a master's degree in Clinical and Translational Science from the UAB School of Public Health during her fellowship training period.

Dr. Bansal has been on faculty at Mount Sinai since 2001. In addition to maintaining an NIH funded research program focused on molecular mechanism of liver fibrosis with seminal contributions to our understanding of liver fibrosis in people living with HIV, Dr.

Dr. Lai is an Integrative Hepatologist who holds the Endowed Professorship of Liver Health & Transplantation at the University of California, San Francisco (UCSF).

Jessica Bartholomew, MSN, APRN, FNP-C, is a hepatology nurse practitioner and sub-investigator in Houston, Texas, focused on MASLD/MASH. She serves as Associate Lead for the AASLD MASLD Special Interest Group and is a member of the Global NASH/MASH Advanced Practice Providers (APP) Committee and GHAPP. She is passionate about advancing APP-led care in liver disease and has contributed to published recommendations guiding MASH management for APPs. Her interests include early detection, noninvasive testing, lifestyle modifications, and the evolving therapeutic pipeline.

Anthony Derencius is a Physician Assistant and Clinical Investigator at Pinnacle Clinical Research in San Antonio, Texas. His work experience includes clinical duties and care in general Gastroenterology, General Hepatology, and Transplant Hepatology in outpatient and inpatient roles. He was selected for a 2018 AASLD Foundation NP/PA Clinical Hepatology Fellowship Award and is an active member of both the Hepatology Associates Committee and Special Interest Group. He has served as the Hepatology Associates Committee Liaison to the Emerging Liver Advanced Practice Provider program.

Dr. Jacqueline O'Leary began her pursuit of research as an undergraduate at Stanford investigating drug development, continued at UCSF where she received and MD with thesis for work in cellular and molecular biology. Following her internal medicine residency at UT Southwestern in Dallas, Dr. O'Leary did a GI fellowship and transplant Hepatology fellowship at Massachusetts General Hospital. Her post-doctoral research there at Harvard focused on immunology. Afterward, she completed a Master's in Public Health from the Harvard School of Public Health.

Dr. Monga is the SVC Endowed Chair in Pathobiology and Therapeutics and Professor of Pharmacology and Medicine at the University of Pittsburgh. He is the Chair/Director of the Organ Pathobiology and Therapeutics Institute. He is also the director of the Pittsburgh Liver Research Center, an NIDDK P30 funded Digestive Disease Research Core Center and the program director of the NIBIB-funded predoctoral training program entitled Cellular Approaches to Tissue Engineering and Regeneration. He serves as the Associate Dean of Research for the University of Pittsburgh School of Medicine.